Numerous companies in the healthcare sector are feverishly busy developing obesity drugs, as these products have taken the medical world by storm. One of the more prominent developers, clinical-stage biotech Viking Therapeutics (VKTX +0.04%), saw its share price rise by almost 4% on Thursday on the back of encouraging research about a certain property of such treatments.
The stock’s rise was more than good enough to convincingly beat the 0.3% bump higher of the benchmark S&P 500 index on the day.
Unexpected benefits
Not only are obesity drugs effective in reducing body weight, it seems they have knock-on effects on certain health conditions, too — which is one of the major reasons investors have been hot on companies selling or developing them.
Image source: Getty Images.
Thursday morning, a report published on Fox News’s website detailed a new study indicating that GLP-1 agonists (substances that mimic a hormone that produces a feeling of satiety after eating) can have a positive effect on a particularly bothersome skin condition. This is hidradenitis suppurativa, which is characterized by small lumps that develop under the skin.
Citing research conducted by a group of French doctors and published in the JAMA Dermatology medical journal, the media outlet wrote that GLP-1 agonists appear to have general anti-inflammatory properties. At the very least it seems they might help in the treatment of hidradenitis suppurativa; the researchers found that administration of GLP-1s were “beneficial” to the condition.
Double barreled
Viking’s VK2735 is actually a dual agonist, as it targets not only the GLP-1 receptor but also a receptor known as glucose-dependent insulinotropic polypeptide (GIP).
Regardless, since it’s partially a GLP-1 agonist, it’s likely, if this research is accurate, to benefit those with hidradenitis suppurativa. That would add significantly to its value if Viking manages to fully develop and ultimately commercialize the very promising drug.